Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
95,162,616
-
Share change
-
-1,793,893
-
Total reported value
-
$12,552,502,929
-
Put/Call ratio
-
83%
-
Price per share
-
$131.92
-
Number of holders
-
392
-
Value change
-
+$921,696,752
-
Number of buys
-
238
-
Number of sells
-
259
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q1 2025
As of 31 Mar 2025,
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) was held by
392 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
95,162,616 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., Pentwater Capital Management LP, Davidson Kempner Capital Management LP, OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC), FARALLON CAPITAL MANAGEMENT LLC, FMR LLC, Balyasny Asset Management L.P., CITADEL ADVISORS LLC, and Deep Track Capital, LP.
This page lists
392
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.